# MAP-LUNG

**Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer**




- Collaboration between SWOG, NCI, FNIH, FoCR, advocacy groups, pharma…
- Disease specific umbrella protocol
- Phase 2/3 with registrational intent
  - Randomized vs. SoC
- Central genomic screening (CLIA):
  - Foundation Medicine: NGS test platform
  - Clarient: c-MET IHC
- Between 2013 (initiation) and 2016, the 2L NSCLC landscape had changed.
- USA only (*opening in Canada in 2017)

# National Lung Matrix Trial
# CRUK

| Arm | IMP | Cohort | Histology | Molecular Cohort |
|---|---|---|---|---|
| A | AZD4547 | A1 | NSCLC | FGFR2 or FGFR3 mutation |
| B | Vistusertib (AZD2014) | B1 | NSCLC | TSC1 or TSC2 mutation |
| | | B2 | NSCLC | LKB1 mutation or homozygous deletion |
| C | Palbociclib | C1 | SCC | Homozygous p16 (CDKN2A) loss & Rb-proficient |
| | | C2 | ADC | Homozygous p16 (CDKN2A) loss & Rb-proficient |
| | | C3 | NSCLC | CDK4 amplification & Rb-proficient |
| | | C4 | NSCLC | CCND1 amplification & Rb-proficient |
| | | C5 | NSCLC | LKB1 mutation or homozygous deletion with activated KRAS/MAPK pathway & Rb-proficient |
| | | C6 | ADC | KRAS mutation & Rb-proficient |
| D | Crizotinib | D1 | NSCLC | MET amplification |
| | | D2 | NSCLC | ROS1 gene fusions |
| | | D3 | NSCLC | MET exon 14 mutation which includes splice, deletion and point mutation. |
| E | Selumetinib | E1 | SCC | NF1 mutation |
| | | E2 | ADC | NF1 mutation |
| | | E3 | ADC | NRAS mutation |
| F | AZD5363 | F1 | SCC | PIK3CA mutation |
| | | F2 | SCC | PIK3CA amplification |
| | | F3 | NSCLC | PIK3CA mutation or PIK3CA amplification (ADC)<br>PTEN mutation or PTEN loss (ADC) |
| | | | | AKT mutation (NSCLC) |
| | | F4 | SCC | PTEN loss or PTEN mutation |
| NA | Durvalumab (MEDI4736) | NA1 | NSCLC | No actionable genetic mutations |

- Disease specific umbrella protocol (currently 8 drugs and 18 molecular cohorts)
- Phase 2 signal finding study
- Regional genomic screening:
  - 3 dedicated genotyping centers (Technology Hubs)
  - NGS test platform (Illumina Nextera platform)
  - Evolving platform since 2013
- UK only

# NCI-MATCH

- Disease agnostic umbrella protocol (aiming for rare tumor type, not just the large indications)
- Phase 2 signal finding study for monotherapy testing in non-approved indications.
- Semi-central testing:
  - Central Pathology review (MDACC); 4 library prep and sequencing hubs
  - NGS test platform (ThermoFisher)
  - Evolving platform since 2013
- Opened with 10 arms mid-2015;

had 24 arms mid-2016 and now ≥26

- 20-30 patients per arms
- USA only



# WIN Consortium: WINTHER




- Molecular screening umbrella study
- Dual tumor and normal tissue biopsy
- No specific drug or disease setting
- Hypothesis generating study
- Central genomic screening:
  - DNA seq: FMI
  - RNA: Affy array at IGR
- Started in April 2013.
- Multi center/

Multinational study (US; Canada; EU; Israel)

- Should report this year

# WIN Consortium: SPRING

- Disease specific (NSCLC) umbrella protocol (currently 1 triple combination)
- Triple therapy
- Phase 1/2 dose finding (~30 pts)/signal finding study (~200 pts)
- Central testing:
  - NGS test platform
  - RNA/miRNA test platform
- Multi center/Multinational study
- Should initiate 2017